

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

China NT Pharma Group Company Limited (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) are announce that, the board of directors (the “**Board**”) of the Company are pleased to update the shareholders of the Company and potential investors about completion of profit guarantee on the Associate.

COMPLETION OF PROFIT GUARANTEE ON THE ASSOCIATE

The Company was notified by Beijing Kangchen Biotechnology Company Limited (“**Associate**”), an associate, and its substantial shareholder, Beijing Konruns Pharmaceutical Company Limited (“**Konruns Pharma**”), a company listed on the Main Board of the Shanghai Stock Exchange (stock code: 603590), and its announcement of completion of profit guarantee.

On 21 April, 2020, Konruns Pharma and the Associate entered into the “Payment of Cash for Purchase of Assets Agreement” with the Company, NT Pharma International Company Limited (“**NT International**”), NT Pharma (HK) Company Limited, NT Pharma (Overseas) Holding Company Limited, NT Pharma Pacific Company Limited (“**NT Pacific**”), Suzhou First Pharmaceutical Company Limited and Mr. Ng Tit, a director of the Company, which agreement provides that Konruns Pharma invested RMB900 million to purchase 100% equity interest in NT International after business reorganization. At the same time, it was agreed in the Agreement that upon completion of the acquisition, a subsidiary of the Company, NT Pharma Pacific Limited, would increase its capital to the Associate. In this transaction, the Group are under profit guarantee for the Associate’s Miacalcic related business for the years from 2021 to 2023.

The information of profit guarantee are set out below:

The net profit of the interest-related business covered by the consolidated statements of the Associate in 2021, 2022 and 2023 shall not be less than RMB80 million, RMB100 million and RMB120 million respectively, i.e. a total net profit after tax of not less than RMB300 million for the three years.

Net profit in the consolidated statement of the Associates as recognized by the accounting firm engaged by Konruns Pharma and the Associates to conduct a special audit in accordance with PRC Accounting Standards:

- (1) The net profit and net profit after non-operating profit and loss of the Associate's Miacalcic business for the year 2021 will be RMB81.31 million and RMB81.59 million, respectively, exceeding the guaranteed net profit of RMB1.31 million, and representing 101.64% of the projected profit for the year.
- (2) The net profit and net profit after non-operating profit and loss of the Associate's Miacalcic business for the year 2022 were RMB102,690,000 and RMB102,020,000 respectively, exceeding the guaranteed net profit of RMB2,020,000, and representing 102.02% of the projected profit for the year.
- (3) The net profit and net profit after non-operating profit and loss of the Associate's Miacalcic for the year 2023 amounted to RMB122,890,000 and RMB122,870,000 respectively, exceeding the guaranteed net profit of RMB2,870,000 and representing 102.39% of the projected profit for the year.

In conclusion, the Group has completed the profit guarantee.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 9 May 2025

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Director is Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.